Alaska Permits Opioid Public-Nuisance Claims Against Pharmacies and Clarifies the UTPA Regulatory Exemption

Case: State of Alaska v. Albertsons Companies, Inc.; Albertsons Companies LLC; Safeway, Inc.; Carr-Gottstein Foods Co.; The Kroger Co.; and Fred Meyer, Inc.

Court: Supreme Court of the State of Alaska
Opinion: No. 7836, November 6, 2026
Author: Justice Pate
Disposition: Affirmed in part, reversed in part, and remanded.

1. Introduction

The Alaska Supreme Court held that allegations of systemic, unlawful opioid dispensing by retail pharmacies can support a common-law public-nuisance claim. It rejected a categorical rule excluding claims involving the sale of products. At the same time, it largely upheld dismissal of the State’s claims under the Alaska Unfair Trade Practices and Consumer Protection Act (UTPA), while allowing a distinct allegation of deceptive public promotion to proceed.

The defendants were two groups of pharmacy operators: Albertsons Companies, Inc., Albertsons Companies LLC, Safeway, Inc., and Carr-Gottstein Foods Co., collectively described as “Safeway”; and The Kroger Co. and Fred Meyer, Inc., collectively described as “Kroger.” Other originally named defendants, including Walgreens-related entities and Walmart, had settled and were not parties to the appeal.

Background and allegations

Alaska alleged that the pharmacies disregarded obligations under the federal Controlled Substances Act (CSA), the Alaska Controlled Substances Act (ACSA), and related regulations. According to the complaint, they inadequately monitored suspicious prescriptions and orders, ignored warning signs of diversion, failed to investigate and report suspicious activity, and dispensed opioids without effective controls.

The complaint described consequences extending beyond individual opioid users: overdose deaths, infectious diseases associated with injection drug use, pressure on healthcare and law-enforcement systems, increased foster-care placements, and harms associated with prenatal opioid exposure. It alleged that opioid-overdose hospital visits cost more than $23 million during 2016 and 2017.

The allegations also included defendant-specific conduct. Safeway allegedly delayed reporting employee theft of tens of thousands of hydrocodone tablets, leading to a federal investigation and a $3 million settlement. Kroger allegedly rewarded prescription-filling volume and speed while allowing flagged opioid orders to proceed on minimal explanations. Separately, the State alleged that the pharmacies publicly promoted their compliance efforts in a manner that falsely suggested they were fulfilling their legal obligations.

Issues presented

  1. Whether the pharmacies’ alleged conduct fell within the UTPA exemption for conduct regulated under a state-administered statutory or regulatory scheme.
  2. Whether the alleged consequences of unlawful dispensing implicated collective public rights rather than merely accumulated individual injuries.
  3. Whether public-nuisance law categorically excludes claims involving products.

Procedural qualification: This appeal concerned dismissal under Alaska Civil Rule 12(b)(6). The court accepted the complaint’s factual allegations as true; it did not find that the pharmacies actually committed the alleged misconduct or caused the claimed harms.

2. Summary of the Opinion

Issue Holding Result
UTPA claims based on dispensing and compliance failures The pharmacies demonstrated ongoing, careful regulation, and Alaska law specifically prohibited the alleged conduct. Dismissal affirmed.
UTPA claim based on deceptive public promotion The pharmacies did not establish that the governing pharmacy laws specifically prohibited the alleged misleading promotion of compliance efforts. Dismissal reversed.
Common-law public nuisance The alleged systemic violations sufficiently implicated collective rights to public health and safety. Product sales are not categorically excluded from nuisance law. Dismissal reversed.

The court expressly clarified that defendants need not produce examples of actual enforcement actions to establish the first part of the UTPA exemption. Enforcement authority within an adequate regulatory framework can establish ongoing, careful regulation. The second part remains conduct-specific: the applicable law must prohibit the particular practice alleged.

For public nuisance, the decisive distinction was between merely selling a lawful product and allegedly distributing controlled substances in an unlawful manner. The complaint challenged the pharmacies’ performance of legally imposed gatekeeping duties, not the simple existence of prescription opioids in commerce.

3. Analysis: Pleading Standards and the Limited Appellate Decision

The court reviewed the dismissal de novo, independently determining the governing law. Alaska’s pleading standard required liberal construction of the complaint and acceptance of its factual allegations as true. Dismissal was appropriate only if it appeared beyond doubt that the State could prove no set of facts supporting relief.

Procedural precedents cited

  • Robinson v. Alaska Hous. Fin. Corp., 442 P.3d 763 (Alaska 2019), supplied both the independent standard of review and the demanding threshold for dismissal. Clemensen v. Providence Alaska Med. Ctr., 203 P.3d 1148 (Alaska 2009), supplied the dismissal formulation quoted through that precedent, while Forrer v. State, 471 P.3d 569 (Alaska 2020), reinforced it.
  • Torrence v. Blue, 552 P.3d 489 (Alaska 2024), quoting Patterson v. Walker, 429 P.3d 829 (Alaska 2018), required the court to accept factual allegations and construe the complaint liberally. That principle was particularly important when the pharmacies argued that the deceptive-promotion allegation applied only to defendants who had settled.
  • Armstrong v. Chance, 541 P.3d 1128 (Alaska 2024), quoting Guin v. Ha, 591 P.2d 1281 (Alaska 1979), directed the court to adopt the rule most persuasive in light of precedent, reason, and policy.
  • Larson v. State, Dep't of Corr., 284 P.3d 1 (Alaska 2012), supported liberal construction. Sagoonick v. State, 503 P.3d 777 (Alaska 2022), quoting Catholic Bishop of N. Alaska v. Does 1-6, 141 P.3d 719 (Alaska 2006), reinforced that a potentially provable claim should not be terminated at the pleading stage.

These authorities explain the opinion’s restraint. The State established a legally sufficient route to relief, not entitlement to relief. Questions of evidentiary proof, causation, and appropriate remedies remain for further proceedings.

4. Analysis: The UTPA Regulatory Exemption

A. Broad consumer protection, subject to a specific statutory exception

Alaska Statute 45.50.471(a) prohibits unfair or deceptive acts or practices in trade or commerce. An act may be unfair because it offends established public policy, is immoral or unscrupulous, or causes substantial consumer injury. An act is deceptive if it has the capacity or tendency to deceive.

Nevertheless, AS 45.50.481(a)(1) exempts certain acts or transactions regulated under state-administered statutes or regulations. The exemption requires defendants to establish:

  1. Ongoing, careful regulation of the relevant conduct under an appropriate regulatory scheme; and
  2. A specific prohibition against the conduct alleged to violate the UTPA.

The exemption is therefore neither an industry-wide immunity nor a rule protecting only lawful behavior. Conduct may be prohibited under another regulatory scheme and, for that reason, exempt from this particular consumer-protection statute.

B. First step: enforcement authority, not enforcement examples

The ACSA and related pharmacy laws impose registration, recordkeeping, dispensing, reporting, and diversion-control obligations. The Board of Pharmacy regulates pharmacy practice, can investigate violations, and may impose licensing sanctions and civil penalties. The Department of Public Safety also has enforcement responsibilities and may seek injunctions against unlawful distribution or dispensing.

This was sufficiently comprehensive regulation. The State argued that the pharmacies additionally needed examples showing actual state enforcement. The court rejected that requirement. Otherwise, even a newly enacted, fully equipped regulatory scheme could fail the exemption merely because no enforcement history yet existed.

The distinction is important: examples of enforcement can help explain whether a particular practice is prohibited at the second step, but they are not mandatory proof that the regulatory framework is ongoing and careful at the first step.

C. Federal standards were enforceable through Alaska law

The State also emphasized that the exemption applies to statutes or regulations administered by the State, not merely federal authorities. The court agreed with that statutory premise but rejected its application here. Alaska law incorporates federal controlled-substance requirements and authorizes state officials to administer them. The exemption therefore rested on Alaska’s regulatory framework, not solely on federal oversight.

D. Second step: most allegations were specifically prohibited

The alleged failures to maintain compliance programs, investigate and report suspicious orders, halt improper dispensing, and verify legitimate medical purposes were specifically prohibited under the applicable Alaska statutes and regulations. Dismissal of those UTPA theories was therefore affirmed.

The deceptive-promotion allegation was different. The pharmacies did not establish that pharmacy regulation specifically prohibited misleading public statements about their compliance efforts. Instead, they argued that this allegation concerned only Walgreens and Walmart. Because the complaint attributed the conduct to collectively defined “Defendants,” including Safeway and Kroger, liberal construction defeated that argument.

The court thus reinstated this UTPA theory. It did not determine that any particular statement was false, misleading, or ultimately actionable.

E. UTPA precedents and their influence

Foundational exemption decisions

  • Matanuska Maid, Inc. v. State, 620 P.2d 182 (Alaska 1980), established that the exemption requires “ongoing, careful regulation,” not simply a legal prohibition. It supplied the central distinction between a genuine regulatory regime and a bare rule against misconduct.
  • State v. O'Neill Investigations, Inc., 609 P.2d 520 (Alaska 1980), supported both liberal construction of consumer protection and the significance of regulation under a “separate and distinct statutory scheme.” The pharmacy framework met that description.
  • Adkins v. Collens, 444 P.3d 187 (Alaska 2019), supplied the two-part exemption test. Its discussion of enforcement was relevant to determining whether specific conduct was prohibited, not to creating a universal requirement for enforcement examples.
  • Pepper v. Routh Crabtree, APC, 219 P.3d 1017 (Alaska 2009), provided an important contrast. Attorney-conduct rules and civil-procedure rules did not establish the kind of ongoing, careful regulation necessary for exemption. The court found the pharmacy regime more comprehensive and its enforcement authority more extensive.

Consumer-protection principles and professional regulation

  • Merdes & Merdes, P.C. v. Leisnoi, Inc., 410 P.3d 398 (Alaska 2017), supplied the UTPA’s basic elements, its remedial character, and the standards for unfairness and deception. It also reinforced that professional regulation does not itself create blanket immunity.
  • Kenai Chrysler Ctr., Inc. v. Denison, 167 P.3d 1240 (Alaska 2007), was the source of the two-element UTPA formulation quoted through Merdes & Merdes, P.C. v. Leisnoi, Inc..
  • Alaska Tr., LLC v. Bachmeier, 332 P.3d 1 (Alaska 2014), supported liberal construction of the remedial statute.
  • Borgen v. A &M Motors, Inc., 273 P.3d 575 (Alaska 2012), supplied the unfairness factors and the capacity-or-tendency-to-deceive standard. F.T.C. v. Sperry & Hutchinson Co., 405 U.S. 233 (1972), explained the federal origins of the unfairness factors.
  • Jones v. Westbrook, 379 P.3d 963 (Alaska 2016), confirmed that attorney regulation and UTPA obligations can coexist. Its relevance was comparative: regulation alone is insufficient without satisfying the exemption’s actual requirements.
  • Andrews & Lawrence Pro. Servs., LLC v. Mills, 223 A.3d 947 (Md. 2020), quoting Lockett v. Blue Ocean Bristol, LLC, 132 A.3d 257 (Md. 2016), supported narrowly construing exemptions from remedial legislation.

The previously unresolved enforcement-history question

State v. Janssen Ortho LLC, 2012 WL 13034376 (D. Alaska Mar. 30, 2012), had certified the question whether enforcement examples were necessary to establish ongoing, careful regulation. Settlement prevented an answer. White v. NYLIFE Sec., LLC, 551 F. Supp. 3d 974 (D. Alaska 2021), recounted that history, citing the settlement-related order in Alaska v. Janssen Ortho LLC. These authorities supplied procedural background rather than a controlling answer; the present opinion expressly resolved the question.

5. Analysis: Public Nuisance and Collective Public Rights

A. The governing rule is not confined to land

Under Restatement (Second) of Torts § 821B, a public nuisance is an unreasonable interference with a right common to the general public. Unlike private nuisance, it does not necessarily require interference with land use or enjoyment.

The Restatement identifies several circumstances supporting a finding of unreasonableness: significant interference with public health, safety, peace, comfort, or convenience; conduct prohibited by law; and continuing conduct or lasting effects that the actor knows or should know significantly affect a public right. These are nonexclusive considerations, not a requirement that every nuisance claim satisfy all three.

The court’s historical discussion also resisted a property-only conception. Public nuisance developed to address varied threats to community welfare, including unsafe food, activities endangering public health, and conduct obstructing public functions.

B. Community-wide harm is not merely a numerical aggregation

The pharmacies argued that the complaint described only many individual injuries from opioid use. The court disagreed because the alleged effects impaired community interests independently of the injuries suffered by individual users.

Overburdened emergency and healthcare services, communicable-disease risks, pressure on law enforcement, and disruption of child-protection systems implicate public health and safety collectively. Not every member of the community must suffer the same injury—or any direct physical injury—for a public right to be affected.

The Restatement’s example of a malaria-breeding pond illustrated the distinction. Disease directly injures infected individuals, but maintaining the source of a community-wide disease threat can interfere with public health. Similarly, the State alleged more than isolated dispensing errors: it alleged systemic failures contributing to an epidemic.

C. Preexisting duties limited the theory of liability

The court treated the pharmacies as legally regulated gatekeepers controlling access to dangerous substances. Their alleged failure to perform those duties distinguished the case from a challenge to the ordinary sale of a potentially harmful product.

This reasoning also answered the “floodgates” objection. Public nuisance still requires an unreasonable interference with a public right and causation. Here, specific statutory duties supplied an additional boundary and notice of prohibited conduct. The court did not announce that any product associated with widespread harm becomes a nuisance, nor that every regulatory violation necessarily does so.

D. Alaska and historical precedents

  • Friends of Willow Lake, Inc. v. State, Dep't of Transp. & Pub. Facilities, Div. of Aviation & Airports, 280 P.3d 542 (Alaska 2012), supplied Alaska’s Restatement-based definition of public nuisance. It was central because that definition is broader than a land-based or criminal-conduct-only rule.
  • Maier v. City of Ketchikan, 403 P.2d 34 (Alaska 1965), recognized public nuisance involving a dangerous physical condition affecting people exercising a public right. The court rejected the argument that its factual formulation exhaustively limited all future claims. The opinion acknowledged that the decision was overruled on other grounds by Johnson v. City of Fairbanks, 583 P.2d 181 (Alaska 1978).
  • In re Debs, 158 U.S. 564 (1895), Hill v. Pierson, 63 N.W. 835 (Neb. 1895), and State ex rel. Marron v. Compere, 103 P.2d 273 (N.M. 1940), illustrated nuisance law’s historical application to railway strikes, gambling houses, and incompetent or unlicensed medical practice. Their function was to demonstrate doctrinal breadth, not establish opioid-specific liability.
  • Milwaukee Metro. Sewerage Dist. v. City of Milwaukee, 691 N.W.2d 658 (Wis. 2005), reinforced the distinction between public nuisance and private nuisance: public nuisance need not involve interference with land.

E. Supporting opioid and community-harm decisions

  • Alaska v. Express Scripts, Inc., 2024 WL 2321210 (D. Alaska May 22, 2024), supplied a closely related explanation of collective harm under Alaska law. The court drew on its discussion of public spaces, government services, and communicable-disease risks to explain why opioid-related allegations can implicate community interests.
  • City & Cnty. of San Francisco v. Purdue Pharma L.P., 491 F. Supp. 3d 610 (N.D. Cal. 2020), supported allowing comparable nuisance allegations against opioid manufacturers and distributors to survive dismissal. It also appeared among the authorities addressing causation in nuisance litigation.
  • In re Nat'l Prescription Opiate Litig., 406 F. Supp. 3d 672 (N.D. Ohio 2019), supported the proposition that evidence concerning opioid distribution could permit a jury to find interference with public health and safety.
  • Rhode Island ex rel. Neronha v. Purdue Pharma L.P., 2022 WL 577874 (R.I. Super. Ct. Feb. 18, 2022), similarly treated alleged opioid-related community harms as potentially affecting public rights rather than merely individual interests.

F. Contrary decisions distinguished

State ex rel. Hunter v. Johnson & Johnson

In State ex rel. Hunter v. Johnson & Johnson, 499 P.3d 719 (Okla. 2021), the Oklahoma Supreme Court reversed a nuisance judgment against an opioid manufacturer. It described Oklahoma nuisance liability in terms of criminal nuisances or property-related injury and offensive activity.

Alaska’s Restatement-based law contained no corresponding restriction. The decision was also factually different: Alaska sued dispensing pharmacies for violating duties over conduct directly within their control, whereas Oklahoma challenged a manufacturer’s marketing and sales practices through a longer distribution chain.

The Alaska court therefore rejected both the narrower doctrinal premise and its application to these defendants. It did not purport to decide how every manufacturer-focused claim would fare under Alaska law.

City of Chicago v. Beretta U.S.A. Corp.

In City of Chicago v. Beretta U.S.A. Corp., 821 N.E.2d 1099 (Ill. 2004), Chicago challenged firearm sales allegedly facilitating subsequent unlawful possession and use. The Illinois Supreme Court found no unreasonable interference where the defendants were not alleged to have violated applicable sales laws or negligently distributed firearms. It also questioned, without deciding, whether the claimed public harms merely aggregated individual rights against assault.

The superior court relied on this authority, but the Alaska Supreme Court found a decisive distinction: Alaska alleged violations by the pharmacies themselves of preexisting distribution and dispensing duties. The asserted wrong was not dependent entirely on later unlawful conduct by customers. Those allegations supplied a basis for finding unreasonable interference that was absent from the firearm case.

Other narrower state-law approaches

Kennedy v. Prime Hydration, LLC, 2024 WL 3826529 (W.D. Ky. Aug. 14, 2024), dismissed a nuisance claim under Kentucky’s property-focused approach. Express Scripts, Inc. v. Anne Arundel Cnty., 353 A.3d 1084 (Md. 2026), reflected a Maryland approach the court considered similar to Oklahoma’s. Neither displaced Alaska’s broader common-law standard.

6. Analysis: Why Product Sales Are Not Categorically Excluded

A. The complaint challenged the manner of dispensing

The pharmacies characterized the suit as an attempt to impose nuisance liability for selling lawful products. The court rejected that description. The alleged wrong was dispensing opioids without legally required controls, despite indications of diversion.

This distinction matters because products liability and public nuisance address different legal interests. Products liability ordinarily concerns injuries to particular persons associated with a product. The nuisance theory here concerned unlawful distribution practices allegedly interfering with community-wide health and safety, for which the State sought abatement.

B. Restatement (Third) § 8 did not supply immunity

The pharmacies relied on the Restatement (Third) of Torts: Liability for Economic Harm § 8, which cautions against using nuisance law to address mass harms from dangerous products. The court read that discussion within its stated scope: private claims for economic loss. The comments recognize that public-official nuisance actions have traditionally been broader.

Accordingly, the provision did not establish a categorical defense against Alaska’s public enforcement action. This was not a holding that private plaintiffs may bring identical claims or obtain identical remedies.

C. Control and perpetual-liability concerns

The court also rejected the concern that nuisance liability necessarily continues indefinitely after a product leaves the seller’s hands. The relevant alleged conduct occurred while the pharmacies controlled whether opioids would be dispensed. Their gatekeeping obligations attached at that point.

The mere continued presence of opioids in the market was not the pleaded nuisance. The alleged nuisance arose from systemic failures to apply legally required controls, coupled with collective harm. Liability therefore remained tied to allegedly wrongful conduct, not product existence alone.

D. Principal product-related precedents

City of Huntington v. AmerisourceBergen Drug Corp.

The opinion relied on two decisions bearing this title. City of Huntington v. AmerisourceBergen Drug Corp., 96 F.4th 642 (4th Cir. 2024), supported the limited application of Restatement (Third) § 8 to private suits rather than public-official nuisance actions.

City of Huntington v. AmerisourceBergen Drug Corp., 157 F.4th 547 (4th Cir. 2025), supplied several additional propositions: unlawful conduct can establish unreasonableness; broader common-law nuisance systems differ from Oklahoma’s narrower approach; and nuisance actions seeking public abatement serve a function distinct from individual products-liability actions. The Alaska court expressly adopted its explanation of that remedial distinction.

In re Nat'l Prescription Opiate Litig.: persuasive reasoning, qualified procedural history

In re Nat'l Prescription Opiate Litig., 589 F. Supp. 3d 790 (N.D. Ohio 2022), distinguished harm arising from products themselves from harm arising from how pharmacies dispensed them. It also rejected reliance on Oklahoma’s narrow nuisance doctrine and interpreted Restatement (Third) § 8 as concerning private economic-loss claims.

The Alaska court expressly acknowledged the subsequent limitation on that decision. In re Nat'l Prescription Opiate Litig., 265 N.E.3d 1 (Ohio 2024), held that Ohio’s products-liability statute expressly barred the nuisance claim. The Sixth Circuit consequently vacated the judgment in In re Nat'l Prescription Opiate Litig., 2025 WL 354758 (6th Cir. Jan. 31, 2025).

That statutory development did not control Alaska because Alaska had not enacted a comparable statute. The court therefore retained the federal district court’s common-law reasoning as persuasive while recognizing that its judgment could not stand under Ohio legislation.

Historical product-based nuisance

City of Cincinnati v. Beretta U.S.A. Corp., 768 N.E.2d 1136 (Ohio 2002), recognized a nuisance cause of action involving firearm manufacturing, marketing, distribution, and sales. Along with historical examples involving food unfit for consumption, it undermined the asserted universal rule that product-related conduct has always been outside nuisance law.

The holding was therefore carefully framed: product involvement does not defeat a claim that otherwise satisfies Alaska’s nuisance requirements. Product involvement also does not establish those requirements.

7. Causation and Remedies: What the Opinion Leaves Open

A. Causation remains essential

The State must ultimately prove that the pharmacies caused the alleged interference with public rights. The court identified both factual causation—whether the injury would have occurred but for the defendant’s act—and legal causation—whether the act was sufficiently important that reasonable people would attach responsibility to it.

  • Goodwin v. Mat-Su Midwifery, Inc., 562 P.3d 26 (Alaska 2024), established causation as an essential element of every tort claim.
  • Winschel v. Brown, 171 P.3d 142 (Alaska 2007), supplied the factual-and-legal-causation formulation.
  • Vincent by Staton v. Fairbanks Mem'l Hosp., 862 P.2d 847 (Alaska 1993), explained that the Restatement’s substantial-factor approach encompasses both components.
  • People v. ConAgra Grocery Prod. Co., 227 Cal. Rptr. 3d 499 (Cal. App. 2017), supported applying negligence causation principles to nuisance claims and reinforced that nuisance liability requires a causal contribution to substantial and unreasonable public interference.

Although the superior court referred to an insufficient “nexus,” the Supreme Court interpreted that language as addressing the existence of a public right, not as a separate causation ruling. Its reversal therefore should not be read as an adjudication that particular dispensing practices caused particular statewide expenditures or injuries.

B. Requested relief was not awarded

Under the UTPA, the State sought an injunction, civil penalties of up to $25,000 per violation, and restoration of money obtained from consumers. For nuisance, it sought cessation of the challenged practices and abatement, potentially including addiction treatment and expanded naloxone availability.

The court did not order those measures or decide their permissible scope. Reinstating the claims allows further litigation over liability and appropriate relief; it does not approve every proposed abatement expenditure.

8. Potential Impact

A. A viable, but bounded, route for public-health nuisance litigation

The decision establishes that Alaska public-nuisance law is not limited to property conditions, natural resources, or criminal nuisances. Systemic conduct affecting healthcare capacity, public safety, infectious-disease risks, and government services may implicate collective public rights.

Future plaintiffs must nevertheless explain the public character of the interference. Widespread individual injury, standing alone, does not automatically establish a public nuisance.

B. Strong relevance to regulated intermediaries

The reasoning is especially significant where a defendant has direct control over access to dangerous products and specific duties designed to protect the public. Such duties can help establish unreasonableness and distinguish ordinary commercial activity from allegedly wrongful distribution practices.

The opinion does not make statutory violations indispensable to every nuisance claim. Rather, they were a particularly important limiting and supporting feature of this claim.

C. Different consequences for different legal theories

The same regulatory scheme can exempt conduct from the UTPA while supporting a common-law nuisance allegation. There is no contradiction: the UTPA exemption allocates statutory coverage, while nuisance law independently addresses unreasonable interference with public rights.

Businesses therefore cannot treat UTPA exemption as general immunity from civil liability. Conversely, plaintiffs cannot assume that conduct violating another statute necessarily creates an additional UTPA claim.

D. Conduct-specific pleading and exemption analysis

The surviving deceptive-promotion theory illustrates the need to analyze each alleged practice separately. A business’s dispensing operations may be comprehensively regulated while public statements about its compliance remain outside the exemption.

Defendants invoking the exemption must connect the particular allegation to a specific regulatory prohibition. Showing that the business operates in a regulated sector is insufficient.

E. Legislative context will remain important

The Ohio litigation demonstrates that statutory displacement can alter the result even where common-law reasoning favors a nuisance claim. Alaska’s refusal to create a judicial products exception rests partly on the absence of comparable Alaska legislation. The decision does not resolve how any future statutory change would operate.

9. Complex Concepts Simplified

Public nuisance
Conduct that unreasonably interferes with a community right, such as public health or safety—not simply conduct that injures many separate people.
Private nuisance
Interference with a person’s use or enjoyment of land. Public nuisance is not confined to that property-based interest.
Opioid diversion
The unlawful movement of regulated drugs from legitimate medical channels into unauthorized use or distribution.
Gatekeeping duty
A legal responsibility to control access. Here, pharmacies allegedly had duties to assess warning signs and prevent improper dispensing of controlled substances.
Regulatory exemption
A statutory rule excluding certain conduct from UTPA coverage because another sufficiently comprehensive state-administered framework regulates and specifically prohibits it.
Abatement
Measures aimed at stopping or reducing a nuisance and its effects. The State proposed treatment and naloxone-related measures, but their availability was not decided.
Actual and legal causation
Whether the conduct made the necessary factual difference to the harm, and whether its contribution was important enough to justify legal responsibility.
De novo review
Independent appellate review of a legal question without deferring to the lower court’s legal conclusion.
Surviving a motion to dismiss
Establishing that the allegations could support legal relief if proved. It is permission to continue litigating, not a finding that the allegations are true.

10. Conclusion

The opinion establishes that allegedly unlawful opioid dispensing can support an Alaska public-nuisance claim when it unreasonably interferes with collective public health and safety. Product sales create no categorical defense, but causation and the other nuisance elements remain essential.

For the UTPA, the court clarified that enforcement examples are unnecessary to establish ongoing, careful regulation, while preserving the requirement of a specific prohibition covering each alleged practice. That distinction exempted most dispensing-related allegations but allowed the deceptive-promotion theory to proceed.

The decision’s central significance is its separation of regulatory coverage, commercial conduct, and collective harm. It permits further adjudication of the State’s claims without converting either regulatory violations or widespread product-related injuries into automatic liability.

This commentary addresses the supplied opinion, which states that it is subject to correction before publication in the Pacific Reporter.